Daewoong Pharmaceutical Unveils Promising Phase 1 Trial Results for New Autoimmune Drug Plodicitinib
Daewoong Pharmaceutical Unveils Promising Phase 1 Trial Results for Plodicitinib
On November 9, 2026, Daewoong Pharmaceutical Co., led by Co-CEOs Seongsoo Park and Changjae Lee, made headlines at the prestigious American College of Rheumatology (ACR) Convergence 2026 conference by presenting their latest advancement in autoimmune disease treatment: Plodicitinib (also known as DWP212525). This promising drug candidate is currently under investigation through a series of clinical trials aimed at treating autoimmune and inflammatory diseases.
Overview of Plodicitinib
Plodicitinib is an oral medication designed to tackle autoimmune diseases by selectively inhibiting specific pathways. It focuses on JAK3, ITK, and BTK—key regulators that govern the activity and function of immune cells. This unique mechanism sets it apart from existing therapies that typically target either T cells or B cells alone. By effectively modulating the immune response, Plodicitinib holds potential for treating a wide array of autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome.
Phase 1 Clinical Trial Findings
During the ACR meeting, Hyemi Park, the Clinical Development Center Program Lead at Daewoong, presented critical findings from a Phase 1 single-ascending dose (SAD) clinical trial. The trial enrolled 44 healthy adults and provided a first glimpse into Plodicitinib's profile as a potential therapeutic agent. The results highlighted that the primary targets, BTK and ITK, achieved over 90% occupancy—a significant indicator showing the drug's potential to effectively engage these crucial immune components.
Further analysis uncovered that drug exposure in participants increased proportionally with higher doses. Importantly, the safety evaluation noted that there were no serious adverse events reported throughout the study duration, and any treatment-related adverse events were classified as mild. This indicates a favorable safety profile, a crucial cornerstone for any new drug.
Professor Seunghwan Lee from Seoul National University Hospital, who oversees the clinical trial, emphasized the optimism surrounding the MAD (multiple-ascending dose) studies. He noted, “No significant safety concerns were evident during the SAD study, suggesting a good tolerability profile that we anticipate will carry over into the upcoming studies.”
Looking Ahead
Following the completion of the SAD phase, Daewoong is advancing into the MAD study, targeting completion of the Phase 1 trials by the first quarter of 2027. CEO Seongsoo Park expressed enthusiasm about the preliminary findings, indicating they serve as strong support for the drug's ongoing development: “The impressive target occupancy rates reinforce our commitment to furthering the clinical development of Plodicitinib, and we are dedicated to exploring its vast potential in various autoimmune diseases.”
Daewoong Pharmaceutical’s ambitious journey with Plodicitinib exemplifies the company's drive to innovate in the healthcare sector, especially in the realm of autoimmune disorders. As research progresses, the medical community and patients alike remain hopeful that Plodicitinib could offer new avenues for effective treatment.